Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Downgraded by Zacks Research to Strong Sell

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) was downgraded by Zacks Research from a “hold” rating to a “strong sell” rating in a research report issued on Thursday, Zacks reports.

Other analysts have also recently issued reports about the stock. Truist Financial dropped their target price on shares of Fresenius Medical Care AG & Co. KGaA from $25.00 to $24.00 and set a “hold” rating on the stock in a report on Monday, October 12th. BNP Paribas Exane lowered Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “underperform” rating and set a $19.90 price objective for the company. in a research report on Tuesday, July 28th. Berenberg Bank set a $24.00 target price on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Tuesday, September 29th. Sanford C. Bernstein raised their price target on Fresenius Medical Care AG & Co. KGaA from $25.50 to $25.80 and gave the company a “market perform” rating in a report on Thursday, August 6th. Finally, Weiss Ratings raised Fresenius Medical Care AG & Co. KGaA from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, October 8th. Seven research analysts have rated the stock with a Hold rating and four have issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Reduce” and an average target price of $23.42.

Fresenius Medical Care AG & Co. KGaA Stock Up 0.1%

NYSE FMS traded up $0.03 during trading hours on Thursday, reaching $22.16. 620,732 shares of the company traded hands, compared to its average volume of 1,011,595. The stock has a market capitalization of $11.90 billion, a PE ratio of 11.48, a PEG ratio of 4.09 and a beta of 0.74. The company has a current ratio of 1.07, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. Fresenius Medical Care AG & Co. KGaA has a 12 month low of $20.02 and a 12 month high of $27.43. The company has a 50 day moving average of $22.65 and a two-hundred day moving average of $22.88.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last released its earnings results on Monday, August 3rd. The company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.62 by $0.04. The company had revenue of $5.55 billion during the quarter, compared to the consensus estimate of $5.48 billion. Fresenius Medical Care AG & Co. KGaA had a net margin of 4.83% and a return on equity of 9.28%. As a group, equities analysts expect that Fresenius Medical Care AG & Co. KGaA will post 2.25 earnings per share for the current year.

Institutional Trading of Fresenius Medical Care AG & Co. KGaA

Several hedge funds and other institutional investors have recently modified their holdings of the company. Tidal Investments LLC grew its stake in Fresenius Medical Care AG & Co. KGaA by 96.0% in the second quarter. Tidal Investments LLC now owns 99,790 shares of the company’s stock valued at $2,256,000 after purchasing an additional 48,885 shares in the last quarter. Moran Wealth Management LLC increased its position in Fresenius Medical Care AG & Co. KGaA by 31.5% in the 1st quarter. Moran Wealth Management LLC now owns 347,773 shares of the company’s stock worth $7,846,000 after purchasing an additional 83,311 shares during the last quarter. Royal Bank of Canada increased its position in Fresenius Medical Care AG & Co. KGaA by 479.2% in the 1st quarter. Royal Bank of Canada now owns 216,861 shares of the company’s stock worth $4,893,000 after purchasing an additional 179,418 shares during the last quarter. Pzena Investment Management LLC raised its stake in shares of Fresenius Medical Care AG & Co. KGaA by 2.0% during the 1st quarter. Pzena Investment Management LLC now owns 15,052,822 shares of the company’s stock worth $339,592,000 after purchasing an additional 299,986 shares in the last quarter. Finally, Ritholtz Wealth Management raised its stake in shares of Fresenius Medical Care AG & Co. KGaA by 252.7% during the 1st quarter. Ritholtz Wealth Management now owns 84,658 shares of the company’s stock worth $1,910,000 after purchasing an additional 60,652 shares in the last quarter. 8.37% of the stock is currently owned by hedge funds and other institutional investors.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA is a Germany-based health care company focused on the treatment of chronic kidney disease and kidney failure. The company provides dialysis care through a global network of outpatient clinics and supports patients with related medical services, including vascular access care, laboratory services and care coordination.

In addition to operating dialysis facilities, Fresenius Medical Care develops and manufactures products used in dialysis treatment.